Overview

• Evaxion Q3 net income $4.6 mln, a turnaround from $1.9 mln loss last year

• Revenue of $7.5 mln in Q3, primarily from MSD option exercise

• Evaxion extends cash runway to second half of 2027 after MSD payment

Outlook

• Company highlights ongoing partnership discussions amid financial market uncertainties

• Evaxion extends cash runway to second half of 2027

• Company aims to enter at least one more partnership deal in coming months

Result Drivers

• Research and development (R&D) expenses were $3.1 million for the period ending September 30, 2025, compared to $2.6 million last year

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Evaxion A/S is $11.00, about 48.5% above its November 5 closing price of $5.66

Press Release: ID:nGNX94BchG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)